- Conditions
- Alzheimer's Disease
- Interventions
- CAD106, Placebo, Alum, MF59
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Up to 85 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 1,758
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Eye
- Interventions
- Secukinumab 10 mg/kg, Canakinumab 10 mg/kg, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Lymphoma, Mantle- Cell
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 31
- States / cities
- Multiple Locations, Arizona • Fayetteville, Arkansas • Concord, California + 25 more
- Conditions
- Kidney Transplantation
- Interventions
- EC-MPS, Tacrolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 291 participants
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Fingolimod
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 60 more
- Conditions
- Symptomatic Knee Osteoarthritis
- Interventions
- DFV890, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • El Cajon, California • Colorado Springs, Colorado + 4 more
- Conditions
- Acute Leukemias
- Interventions
- LDE225
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Acute Heart Failure
- Interventions
- RLX030, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 105
- States / cities
- Huntsville, Alabama • Montgomery, Alabama • Tucson, Arizona + 76 more
- Conditions
- Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
- Interventions
- LTT462
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Kirksville, Missouri
- Conditions
- Asthma
- Interventions
- QAW039, Placebo QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 30
- States / cities
- Encinitas, California • Huntington Beach, California • Los Angeles, California + 24 more
- Conditions
- Metastases, Brain
- Interventions
- capecitabine, lapatinib, trastuzumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 17
- States / cities
- Goodyear, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 14 more
- Conditions
- Chronic Myelogenous Leukemia in Chronic Phase
- Interventions
- Nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 32
- States / cities
- Anaheim, California • Burbank, California • Concord, California + 27 more
- Conditions
- C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
- Interventions
- LNP023
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2036
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
- Conditions
- Acromegaly
- Interventions
- Pasireotide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • New York, New York
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- LCZ696
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 22
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 18 more
- Conditions
- Leukemia
- Interventions
- Interview & Questionnaires, Rating Questionnaire, MDASI-CML Questionnaire
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
- Interventions
- LFF269, Placebo to LFF269
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hypertension
- Interventions
- Valsartan + HCTZ, Valsartan, HCTZ
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 70 Years and older
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Escondido, California + 17 more
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocytopenia
- Interventions
- Panobinostat
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Duarte, California • Stanford, California + 6 more
- Conditions
- Coronary Artery Disease
- Interventions
- Inclisiran sodium 300 mg, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
- Interventions
- 225Ac-ETN029, 111In-ETN029
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more
- Conditions
- HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
- Interventions
- L-NMMA
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Houston, Texas
- Conditions
- Breast Cancer, Colon Cancer, Ovarian Cancer, Endometrium Cancer
- Interventions
- BKM120
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee